Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Surender Kharbanda is active.

Publication


Featured researches published by Surender Kharbanda.


Journal of Biological Chemistry | 1997

Binding of Ku and c-Abl at the kinase homology region of DNA-dependent protein kinase catalytic subunit.

Shengfang Jin; Surender Kharbanda; Bruce J. Mayer; Donald W Kufe; David Weaver

The DNA-dependent protein kinase (DNA-PK) controls the repair of double-stranded DNA breaks in mammalian cells. The protein kinase subunit of DNA-PK (DNA-PKcs) is targeted to DNA breaks by association with the Ku DNA-binding heterodimer. Here we show that a Ku association site is present at the carboxyl terminus of DNA-PKcs (amino acids 3002–3850) near the protein kinase domain. Correspondingly, the nuclear c-Abl tyrosine kinase that associates with DNA-PK also binds to the kinase homology domain. The c-Abl SH3 domain binds to amino acids 3414–3850 of DNA-PKcs. c-Abl phosphorylates C-terminal fragments of DNA-PKcs, particularly amino acids 3414–3850. c-Abl phosphorylation of DNA-PKcs disassociates the DNA-PKcs·Ku complex. Thus, Ku and c-Abl provide opposing functions with regard to DNA-PK activity.


Archive | 1999

Involvement of c-Abl Tyrosine Kinase in Apoptotic Response to Anticancer Agents

Zhi-Min Yuan; Surender Kharbanda; Ralph R Weichselbaum; Donald W Kufe

The cellular response to anticancer agents that damage DNA includes cell-cycle arrest, activation of DNA repair; and induction of apoptosis. However, the signals that determine cell fate, that is, survival or apoptosis, are largely unknown. The c-Abl tyrosine kinase is activated by diverse types of DNA damage. The available information supports a model in which certain sensors of DNA lesions activate the c-Abl kinase. Other findings support a proapoptotic function for the activated c-Abl kinase that is mediated by at least several downstream effectors known to be associated with the induction of apoptosis.


Archive | 2004

Modulation of Muc1 Mediated Signal Transduction

Michael P. Belmares; Peter S. Lu; Jonathan David Garman; Albert A. Jecminek; Surender Kharbanda; Naoki Agata; Donald W Kufe


Archive | 2003

Muc1 interference rna compositions and methods derived therefrom

Donald W Kufe; Surender Kharbanda; Steven Weitman


Archive | 1996

Methods and compositions including dna damaging agents and tyrosine kinase inhibitors or activators

Ralph R. Weichselbaum; Donald W Kufe; Surender Kharbanda


Archive | 2013

ANTI-MUC1 ANTIBODIES FOR CANCER DIAGNOSTICS

Donald W Kufe; Surender Kharbanda


Archive | 2012

Muc1 ligand traps for use in treating cancers

Donald W Kufe; Surender Kharbanda


Archive | 2011

Improved antagonists of muc1

Donald W Kufe; Surender Kharbanda


Archive | 2015

MUC-1 CYTOPLASMIC DOMAIN PEPTIDES AS CANCER INHIBITORS

Donald W Kufe; Surender Kharbanda


Archive | 2012

Pièges de ligand de muc1 pour l'utilisation dans le traitement de cancers

Donald W Kufe; Surender Kharbanda

Collaboration


Dive into the Surender Kharbanda's collaboration.

Top Co-Authors

Avatar

Donald W Kufe

Howard Hughes Medical Institute

View shared research outputs
Top Co-Authors

Avatar

Steven Weitman

University of Texas Health Science Center at San Antonio

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Bruce J. Mayer

University of Connecticut Health Center

View shared research outputs
Top Co-Authors

Avatar

David Weaver

Howard Hughes Medical Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ralph R Weichselbaum

University of Alabama at Birmingham

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge